Ashley N Brown

Ashley N Brown,

PRG DIR & ASO PROF

Department: MD-INST FOR THERAPEUTIC INNOV
Business Phone: (407) 313-7063
Business Email: ashleybrown@ufl.edu

Publications

2021
Antiviral Activity of the PropylamylatinTM Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions.
Viruses. 13(3) [DOI] 10.3390/v13030415. [PMID] 33807769.
2021
Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus.
Viruses. 13(5) [DOI] 10.3390/v13050771. [PMID] 33925551.
2021
Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines.
Microorganisms. 9(2) [DOI] 10.3390/microorganisms9020307. [PMID] 33540830.
2020
Modeling the viral dynamics of SARS-CoV-2 infection.
Mathematical biosciences. 328 [DOI] 10.1016/j.mbs.2020.108438. [PMID] 32771304.
2018
A sensitive electrochemical immunosensor for label-free detection of Zika-virus protein.
Scientific reports. 8(1) [DOI] 10.1038/s41598-018-28035-3. [PMID] 29946074.
2018
Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM).
Viruses. 10(6) [DOI] 10.3390/v10060317. [PMID] 29890736.
2018
Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy. 62(9) [DOI] 10.1128/AAC.00967-18. [PMID] 29967017.
2018
Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 111:443-449 [DOI] 10.1016/j.ejps.2017.10.027. [PMID] 29079337.
2018
The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines.
Antiviral chemistry & chemotherapy. 26 [DOI] 10.1177/2040206618807580. [PMID] 30354193.
2018
Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer.
Frontiers in pharmacology. 9 [DOI] 10.3389/fphar.2018.00403. [PMID] 29765318.
2018
Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens.
Antimicrobial agents and chemotherapy. 62(1) [DOI] 10.1128/AAC.01983-17. [PMID] 29109164.
2017
Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
Pharmacological research. 124:20-33 [DOI] 10.1016/j.phrs.2017.07.015. [PMID] 28735000.
2017
Reply to Scagnolari et al.
The Journal of infectious diseases. 215(3):493-494 [DOI] 10.1093/infdis/jiw580. [PMID] 28003357.
2017
Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.
Antiviral research. 146:149-152 [DOI] 10.1016/j.antiviral.2017.09.001. [PMID] 28882564.
2017
Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).
Scientific reports. 7(1) [DOI] 10.1038/s41598-017-15007-2. [PMID] 29089577.
2016
Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a.
The Journal of infectious diseases. 214(8):1192-7 [DOI] 10.1093/infdis/jiw358. [PMID] 27496974.
2015
Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.
Antimicrobial agents and chemotherapy. 59(7):3771-7 [DOI] 10.1128/AAC.00469-15. [PMID] 25870053.
2015
Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
mBio. 6(6):e01741-15 [DOI] 10.1128/mBio.01741-15. [PMID] 26530386.
2012
Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.
Antimicrobial agents and chemotherapy. 56(3):1170-81 [DOI] 10.1128/AAC.05383-11. [PMID] 22155837.
2011
Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.
Antimicrobial agents and chemotherapy. 55(4):1747-53 [DOI] 10.1128/AAC.01629-10. [PMID] 21263045.
2011
Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.
Antimicrobial agents and chemotherapy. 55(4):1740-6 [DOI] 10.1128/AAC.01628-10. [PMID] 21263046.
2010
In vitro system for modeling influenza A virus resistance under drug pressure.
Antimicrobial agents and chemotherapy. 54(8):3442-50 [DOI] 10.1128/AAC.01385-09. [PMID] 20498316.
2010
Persistence of West Nile virus in the central nervous system and periphery of mice.
PloS one. 5(5) [DOI] 10.1371/journal.pone.0010649. [PMID] 20498839.
2007
Tissue tropism and neuroinvasion of West Nile virus do not differ for two mouse strains with different survival rates.
Virology. 368(2):422-30 [PMID] 17675128.
View on: PubMed

Grants

Jul 2021 ACTIVE
Are We Truly Protected- Assessment of Immunity Protection Against Mutating COVID-19 Strains & Assay Development
Role: Principal Investigator
Funding: ABSS SOLUTIONS via US AIR FORCE
Feb 2021 – Jun 2021
Evaluation of air purification methods for SARS-CoV-2
Role: Principal Investigator
Funding: HELEN OF TROY
Dec 2020 – Jun 2021
COVID-19: Monoclonal Antibody Production
Role: Co-Investigator
Funding: LIFESOUTH COM BLOOD CNTR
Nov 2020 ACTIVE
Evaluation of escape mutants to ADG20 against SARS-CoV-2 virus using a hollow fiber infection model system
Role: Principal Investigator
Funding: ADAGIO THERAPEUTICS
Jul 2020 – Aug 2020
Rapid Inactivation of SARS-CoV-2 by Puradigm Technology
Role: Principal Investigator
Funding: PURADIGM LLC
Jul 2020 – Jul 2021
COVID-19: Sx and other mixes of acids and esters to inactivate SARS-CoV-2 and other viruses
Role: Principal Investigator
Funding: ECOPLANET
Jun 2020 – Jul 2020
COVID19: Inactivation of SARS-CoV-2 by Puradigm Technology
Role: Principal Investigator
Funding: PURADIGM LLC
Apr 2020 – Jul 2020
COVID-19: Antiviral Evaluations for Four Compounds against a Human SARS-CoV-2 Isolate
Role: Principal Investigator
Funding: GLOBAL BIOLIFE
Apr 2019 ACTIVE
SBIR: Microneedle Delivery of Zanamivir for Treatment of Influenza Infections
Role: Principal Investigator
Funding: THERAPEUTIC SYSTEMS RES LABORATORIES via NATL INST OF HLTH NIAID
Jan 2018 – Jun 2019
CZ-02 pharmacodynamic studies, A New Class of Antibiotics Selectively Inhibiting Bacterial Protein Synthesis
Role: Co-Investigator
Funding: CURZA via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Apr 2017 – Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Mar 2017 – Jun 2018
Identification of antiviral therapies for the treatment of Zika virus using existing drugs
Role: Principal Investigator
Funding: FL DEPT OF HLTH
Dec 2015 – May 2021
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Dec 2015 – Nov 2017
Prevalence and mechanism of baseline Nitroimidazole resistance in MDR and XDR TB
Role: Principal Investigator
Funding: BRIGHAM AND WOMENS HOSPITAL via NATL INST OF HLTH
Mar 2014 ACTIVE
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID

Teaching Profile

Courses Taught
2019-2021
PHA7979 Advanced Research
2016-2018,2020
PHA5755 Micro, Immun, Virol
2018-2020
PHA7980 Research for Doctoral Dissertation
2019-2021
PHA6133 Translational Clinical Pharmacology
2018
GMS7979 Advanced Research
2017
PHA6935 Selected Topics in Pharmacy

Contact Details

Phones:
Business:
(407) 313-7063
Emails: